APGE VS FLGT Stock Comparison
Performance
APGE28/100
28/100
APGE returned -16.93% in the last 12 months. Based on SPY's performance of -13.93%, its performance is below average giving it a score of 28 of 100.
FLGT10/100
10/100
FLGT returned -25.11% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Earnings
APGE100/100
100/100
APGE has missed earnings 1 times in the last 20 quarters.
FLGT34/100
34/100
FLGT has missed earnings 4 times in the last 20 quarters.
Volatility
APGE44/100
44/100
APGE has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.
FLGT47/100
47/100
FLGT has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.
Analyst Price Targets
APGE
"Analyst Price Targets" not found for APGE
FLGT67/100
67/100
3 analysts offer 12-month price targets for FLGT. Together, they have an average target of 45, the most optimistic target put FLGT at 50 within 12-months and the most pessimistic has FLGT at 40.
Sentiment
APGE
"Sentiment" not found for APGE
FLGT70/100
70/100
FLGT had a bullish sentiment score of 69.90% across Twitter and StockTwits over the last 12 months. It had an average of 4.32 posts, 1.68 comments, and 3.47 likes per day.
Technicals
APGE
"Technicals" not found for APGE
FLGT61/100
61/100
FLGT receives a 60 of 100 based on 14 indicators. 8 are bullish, 5 are bearish.
Profit
APGE
"Profit" not found for APGE
FLGT53/100
53/100
Out of the last 20 quarters, FLGT has had 12 profitable quarters and has increased their profits year over year on 6 of them.
All score calculations are broken down here to help you make more informed investing decisions
Apogee Therapeutics, Inc. Common Stock Summary
Nasdaq / APGE
Healthcare
Biotechnology
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
Fulgent Genetics, Inc. Common Stock Summary
Nasdaq / FLGT
Healthcare
Medical - Diagnostics & Research
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare APGE to other companies in the same or a similar industry.